These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 28721832)

  • 1. Biomarkers Associated with Bleeding Risk in the Setting of Atrial Fibrillation.
    Sideris S; Archontakis S; Latsios G; Lazaros G; Toutouzas K; Tsiamis E; Vavuranakis M; Vlachopoulos C; Gatzoulis K; Tsioufis C; Tousoulis D
    Curr Med Chem; 2019; 26(5):824-836. PubMed ID: 28721832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study.
    Hijazi Z; Oldgren J; Lindbäck J; Alexander JH; Connolly SJ; Eikelboom JW; Ezekowitz MD; Held C; Hylek EM; Lopes RD; Siegbahn A; Yusuf S; Granger CB; Wallentin L;
    Lancet; 2016 Jun; 387(10035):2302-2311. PubMed ID: 27056738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.
    Hijazi Z; Oldgren J; Andersson U; Connolly SJ; Eikelboom JW; Ezekowitz MD; Reilly PA; Yusuf S; Siegbahn A; Wallentin L
    Am Heart J; 2017 Aug; 190():94-103. PubMed ID: 28760218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation.
    Hijazi Z; Aulin J; Andersson U; Alexander JH; Gersh B; Granger CB; Hanna M; Horowitz J; Hylek EM; Lopes RD; Siegbahn A; Wallentin L;
    Heart; 2016 Apr; 102(7):508-17. PubMed ID: 26839066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the CHA
    Yao X; Gersh BJ; Sangaralingham LR; Kent DM; Shah ND; Abraham NS; Noseworthy PA
    Am J Cardiol; 2017 Nov; 120(9):1549-1556. PubMed ID: 28844514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study.
    Friberg L; Rosenqvist M; Lip GY
    Eur Heart J; 2012 Jun; 33(12):1500-10. PubMed ID: 22246443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter.
    Cairns JA; Connolly S; McMurtry S; Stephenson M; Talajic M;
    Can J Cardiol; 2011; 27(1):74-90. PubMed ID: 21329865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
    Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
    J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stroke and major bleeding risk in elderly patients aged ≥75 years with atrial fibrillation: the Loire Valley atrial fibrillation project.
    Lip GY; Clementy N; Pericart L; Banerjee A; Fauchier L
    Stroke; 2015 Jan; 46(1):143-50. PubMed ID: 25424474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.
    De Caterina R; Andersson U; Alexander JH; Al-Khatib SM; Bahit MC; Goto S; Hanna M; Held C; Hohnloser S; Hylek EM; Lanas F; Lopes RD; López-Sendón J; Renda G; Horowitz J; Granger CB; Wallentin L;
    Am Heart J; 2016 May; 175():175-83. PubMed ID: 27179738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey.
    Marcucci M; Lip GY; Nieuwlaat R; Pisters R; Crijns HJ; Iorio A
    Am J Med; 2014 Oct; 127(10):979-986.e2. PubMed ID: 24838192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation.
    Renda G; Zimarino M; Ricci F; Piccini JP; Ezekowitz MD; Patel MR; Cappato R; Giugliano RP; De Caterina R
    Am J Med; 2016 Oct; 129(10):1117-1123.e2. PubMed ID: 27262782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bleeding risk assessment in patients with atrial fibrillation who are taking oral anticoagulants.
    Guo Y; Lip GY; Apostolakis S
    Hosp Pract (1995); 2013 Feb; 41(1):71-8. PubMed ID: 23466969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term bleeding risk prediction in 'real world' patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores. The Murcia Atrial Fibrillation Project.
    Esteve-Pastor MA; Rivera-Caravaca JM; Roldan V; Vicente V; Valdés M; Marín F; Lip GYH
    Thromb Haemost; 2017 Oct; 117(10):1848-1858. PubMed ID: 28799620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation.
    Aulin J; Siegbahn A; Hijazi Z; Ezekowitz MD; Andersson U; Connolly SJ; Huber K; Reilly PA; Wallentin L; Oldgren J
    Am Heart J; 2015 Dec; 170(6):1151-60. PubMed ID: 26678637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Vitamins K antagonists in non-valvular atrial fibrillation thromboembolic risk prevention in Burkina Faso.
    Yameogo AR; Kologo JK; Mandi G; Kabore HP; Millogo GR; Seghda AA; Samadoulougou AK; Zabsonre P
    Pan Afr Med J; 2016; 24():108. PubMed ID: 27642447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.
    Di Lullo L; Ronco C; Cozzolino M; Russo D; Russo L; Di Iorio B; De Pascalis A; Barbera V; Galliani M; Vitaliano E; Campana C; Santoboni F; Bellasi A
    Thromb Res; 2017 Jul; 155():38-47. PubMed ID: 28482261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Warfarin therapy for atrial fibrillation in general practice--is bleeding risk underestimated?
    Bratland B; Hornnes MB
    Tidsskr Nor Laegeforen; 2014 Jan; 134(2):175-9. PubMed ID: 24477151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Thromboembolism prophylaxis in old age].
    Röhrig G; Kolb G;
    Z Gerontol Geriatr; 2018 Apr; 51(3):349-363. PubMed ID: 29623408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]).
    Steinberg BA; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Peterson ED; Piccini JP;
    Am J Cardiol; 2017 May; 119(10):1590-1595. PubMed ID: 28363354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.